Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Roche has signed a definitive agreement to acquire Kapa Biosystems, a privately held company that employs proprietary technologies to optimize enzymes for next-generation sequencing as well as polymerase chain reaction and real-time PCR applications.
The results of a large, multicenter prospective clinical study that validates the ability of MeMed’s ImmunoXpert in vitro diagnostic blood test to determine whether a patient has an acute bacterial or viral infection was published in the March 18, 2015 online edition of Plos One.
Terumo BCT has received 510(k) clearance for a labeling change, extending the storage of platelets in plasma from five days to seven days, as well as offering wireless capability for the software applications used with Terumo BCT’s Trima Accel Automated Blood Collection System. This clearance adds to the flexibility and productivity of the Trima Accel system, a device that offers single-needle procedures for a more comfortable donation experience.
Qiagen and Biotype Diagnostics have entered into a partnership to establish Biotype Innovation GmbH. The new company will develop and commercialize molecular diagnostic workflows initially for personalized health care applications based on Qiagen’s proprietary ModaPlex platform, which enables customers to detect, characterize, and measure up to 100 parameters simultaneously.
The Insulin and Proinsulin ELISA kits from Enzo Life Sciences allow for the quantitative determination of insulin and proinsulin in serum and plasma. The kits provide a highly sensitive measurement, detecting as little as 0.622 µIU/mL (insulin) and 0.17 pM (proinsulin), deliver fully quantitative results that surpass semiquantitative Western blot analysis, and can analyze up to 40 samples in duplicate in three hours.
CLSI released new and revised standards on point-of-care testing in relation to glucose measuring and monitoring. “Effects of Different Sample Types on Glucose Measurements, 1st Edition (POCT06-Ed1)” provides information to assist the clinical and point-of-care staff in result and measurement procedure comparisons of glucose tests and is intended for use by clinicians, point-of-care teams, pathologists, laboratory directors, and manufacturers of glucose testing devices.
Illumina launched Illumina SeqLab, an integrated solution for customers with HiSeq X Systems designed to increase laboratory efficiency for population-scale, human whole-genome sequencing.
New England Biolabs has released WarmStart RTx Reverse Transcriptase, a novel, thermostable reverse transcriptase, specifically designed for nucleic acid detection.
Bio-Rad Laboratories released human-serum–based Lyphochek Allergen sIgE quality controls to monitor the precision of in vitro allergy test procedures.
UTAK Laboratories released its SMx (specialty matrix) Product Line. SMx bulk matrices and quality control products are now offered as SMx Oral Fluid, SMx Sweat, SMx Hair, SMx Urine, SMx Serum, SMx Cerebral Spinal Fluid, and SMx Synovial Fluid.
